Archive for October, 2006
October 31st, 2006. Extrapleural Pneumonectomy via a Lower Door Open Thoracotomy with Reconstruction of the Diaphragm and Pericardium Using Autologous Materials for Mesothelioma
The LDO thoracotomy provided a good operative field, especially for the costo- and cardiophrenic angles, allowing a complete resection of the diaphragm to be performed easily. Furthermore, the reversed LD muscle flap and fascia lata graft proved to be ideal autologous materials for reconstruction of both the diaphragm and the pericardium.
October 28th, 2006. Can pemetrexed help in malignant mesothelioma?
Currently, this is the only chemotherapy regimen licensed for patients with malignant pleural mesothelioma in the UK. Here we review the care of patients with malignant pleural mesothelioma, focusing on what, if anything, pemetrexed might offer such individuals.
October 26th, 2006. Autocrine growth by granulocyte colony-stimulating factor in malignant mesothelioma
An autopsy demonstrated that some of the tumor cells produced G-CSF, but more tumor cells and endothelial cells in the tumor expressed G-CSF receptor. It was hypothesized that an autocrine loop involving G-CSF and the G-CSF receptor greatly accelerated the tumor growth.
October 26th, 2006. Gene Expression Signatures Differentiate Ovarian/Peritoneal Serous Carcinoma from Diffuse Malignant Peritoneal Mesothelioma
Conclusions: Expression profiling separates OC/PPC from DMPM and identifies a number of genes that are differentially expressed in these tumors. The molecular signatures unique to OC/PPC and DMPM should provide a molecular basis to study both tumors and new potential markers for facilitating their differential diagnosis.
October 26th, 2006. Piroxicam and Cisplatin in a Mouse Model of Peritoneal Mesothelioma
Conclusion: These data suggest that piroxicam sensitizes mesothelioma cells to CDDP-induced cytotoxicity by modulating the expression of several target genes. Therefore, piroxicam in combination with CDDP might potentially be useful in the treatment of patients with mesothelioma.
October 25th, 2006. Malignant pleural mesothelioma: A new standard of care
A rise in the incidence of this fatal disease, which, in the past has been considered to be relatively refractory to therapy, is predicted over the next decade. The realisation that patients can benefit from systemic chemotherapy and more aggressive multimodal approaches, including extrapleural pneumonectomy (EPP), in earlier stages of disease now provides the opportunity to offer more effective treatment for this disease.
October 25th, 2006. Intraoperative localization of lymph node metastases with a replication-competent herpes simplex virus
Conclusions: Herpes virus-guided cancer cell-specific production of green fluorescent protein can facilitate accurate localization of lymph node metastases. Fluorescent filters that detect green fluorescent protein can be incorporated into operative scopes to precisely localize and biopsy lymph node metastases.
October 24th, 2006. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update
This article provides a critical review of all of the information that is presently available on those markers that are believed to have the greatest potential for assisting in distinguishing between epithelioid mesotheliomas and those carcinomas with which they are most likely to be confused. Information is also provided regarding the panels of immunohistochemical markers that are, at present, recommended in these differential diagnoses.
October 24th, 2006. Feasibility of Boron Neutron Capture Therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis
Conclusions: From a viewpoint of the dose–distribution analysis, BNCT has the possibility to be a promising treatment for MPM patients who are inoperable because of age and other medical illnesses.
October 20th, 2006. EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma
EGFR expression in MM correlates with epithelioid histology and TN. EGFR may be a target for selective therapies in MM.
October 19th, 2006. Sex difference in diffuse malignant peritoneal mesothelioma
Conclusions: Women with DMPM had better survival. This observation may be related to the favourable clinical and histopathological features associated with women.
October 17th, 2006. Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach
The current state of the art with respect to the morphological, immunohistological, and molecular features that can assist in the evaluation of benign and malignant pleural disease is examined. Practical guidelines are offered that should reduce the risk of diagnostic error in this problematic area of surgical pathology.
October 17th, 2006. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion
Conclusions: Our studies confirm the role of the above panel of antibodies in distinguishing among these malignancies. Positive staining for K903, CK 5/6, and CAM 5.2 separated SCC and MM from ADC. Positive staining for calretinin separated MM from SCC and ADC. Positive staining for glycoproteins and predominantly negative staining for CK 5/6, K903 and calretinin separated ADC from SCC and MM.
October 17th, 2006. Pathological recognition of diffuse malignant mesothelioma of the pleura: the significance of the historical perspective as regards this signal tumor
Because DMM is increasing on a worldwide basis and is making its appearance in the developing world, where it has not previously been diagnosed, appreciation of how the disease came to be noticed sheds light on its causation. As a signal tumor for exposure to asbestos, and knowing that all special exposures contribute to the development of the disease, knowledge of its continuing escalation underscores the importance of recognition of previously unimplicated or occult exposures for reasons of public health in both developed and developing countries.
October 17th, 2006. The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma
The methods used were immunohistochemistry, Western blotting, and RT-PCR. DMPM specimens showed significantly higher expression of p75 (P.
October 17th, 2006. Spindle cell tumors of the pleura: differential diagnosis
Desmoplastic malignant mesothelioma is a fibrous sarcomatoid variant of malignant mesothelioma, and is occasionally mistaken for chronic fibrous pleurisy. Here, we review morphological, clinical, histological, immunohistochemical, ultrastructural, and molecular methods that aid in the diagnosis of spindle cell tumors of the pleura, and we provide specific examples of patients in which this multi-modal approach proved to be helpful.
October 17th, 2006. The pathogenesis of mesothelioma
These findings indicate that the risk varies among asbestos- and erionite-exposed individuals because of their genetic background or because of exposure to other carcinogens. Moreover, these data provide a rationale for the observation that only a fraction of heavily exposed asbestos workers developed mesothelioma, and novel targets for prevention and therapy.
October 17th, 2006. Molecular tumor markers for asbestos-related mesothelioma: Serum diagnostic markers
It has also been found that N-ERC/mesothelin is very stable and plentiful in the blood. In the present paper the potential utility of molecular diagnostic markers is reviewed, including ELISA systems for asbestos-related mesothelioma.
October 17th, 2006. The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity
There is a modest salutary effect when the pemetrexed target is GARFT alone. [Mol Cancer Ther 2006;5(10):2549–55].
|
|  |
